MAPK8 and prostate carcinoma: Recent studies have found that JNK activation enhanced chemotherapy-induced apoptosis in multiple cancer cells [11], while in prostate cancer, especially in tumors that harbor mutations in PTEN, activated JNK1/2 supports proliferation and survival [23, 24].